Concord Biotech バランスシートの健全性
財務の健全性 基準チェック /56
Concord Biotech has a total shareholder equity of ₹15.3B and total debt of ₹97.4M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹17.0B and ₹1.7B respectively. Concord Biotech's EBIT is ₹4.0B making its interest coverage ratio -395.1. It has cash and short-term investments of ₹2.8B.
主要情報
0.6%
負債資本比率
₹97.38m
負債
| インタレスト・カバレッジ・レシオ | -395.1x |
| 現金 | ₹2.82b |
| エクイティ | ₹15.27b |
| 負債合計 | ₹1.74b |
| 総資産 | ₹17.01b |
財務の健全性に関する最新情報
財務状況分析
短期負債: CONCORDBIO's short term assets (₹9.0B) exceed its short term liabilities (₹1.4B).
長期負債: CONCORDBIO's short term assets (₹9.0B) exceed its long term liabilities (₹319.1M).
デット・ツー・エクイティの歴史と分析
負債レベル: CONCORDBIO has more cash than its total debt.
負債の削減: Insufficient data to determine if CONCORDBIO's debt to equity ratio has reduced over the past 5 years.
債務返済能力: CONCORDBIO's debt is well covered by operating cash flow (2726.2%).
インタレストカバレッジ: CONCORDBIO earns more interest than it pays, so coverage of interest payments is not a concern.